Jun 10, 2021 / 01:40PM GMT
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD
Good morning, everybody. I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs, and we're very pleased to have you join us this morning at our Virtual Healthcare Conference.
Today, from the company -- from Bristol-Myers, we have Chris Boerner, Chief Commercialization Officer; and Samit Hirawat, who is Chief Medical Officer. Thank you both for taking time out of your day to join us this morning. Really appreciate it.
Again, I have a lot of topics to cover today, but I think one that's obviously front and center for most folks is the recovery from the pandemic.
Questions and Answers:
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MDSo maybe, Chris, I thought you could kick it off and tell us a little bit about what you're seeing with respect to the recovery trends in kind of your key end markets here, both in the U.S. and then also outside the U.S.? And how has May been stacking up versus April?
Christopher S. Boerner